Synlogic and Novavax Face Off in Financial Analysis

Two small-cap biotech firms compete on institutional ownership, profitability, and more

Apr. 13, 2026 at 4:22am

Got story updates? Submit your updates here. ›

An extreme close-up photograph of various medical instruments and laboratory equipment, representing the complex machinery and high-stakes environment of the biotech industry.A detailed look at the inner workings of two small-cap biotech firms competing for investor attention in the volatile medical technology sector.Cambridge Today

Synlogic (NASDAQ:SYBX) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which one is the superior business? This analysis compares the two firms across key metrics like institutional ownership, valuation, risk, and profitability to determine which stock comes out on top.

Why it matters

As investors weigh options in the volatile biotech sector, understanding the relative strengths and weaknesses of similar companies can help inform investment decisions. This analysis provides an in-depth look at two promising but risky small-cap players in the medical space.

The details

The analysis finds that Novavax has higher revenue and earnings than Synlogic, but Synlogic is trading at a lower price-to-earnings ratio, indicating it may be more affordable. Novavax also has a much higher beta of 2.65, meaning its share price is 165% more volatile than the S&P 500, compared to Synlogic's beta of 0.49. In terms of profitability, Novavax beats Synlogic on 10 out of 14 key factors. However, Synlogic has stronger institutional ownership at 63.4% versus Novavax's 53%.

  • The analysis is based on the latest financial data as of April 13, 2026.

The players

Synlogic, Inc.

A clinical-stage biopharmaceutical company that develops synthetic biotics to treat metabolic diseases.

Novavax, Inc.

A biotechnology company that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases.

Got photos? Submit your photos here. ›

The takeaway

This comparison of Synlogic and Novavax highlights the complex tradeoffs investors must weigh when evaluating small-cap biotech stocks. While Novavax has stronger financial metrics overall, Synlogic's lower valuation and institutional backing suggest it may be the more attractive option for risk-tolerant investors seeking exposure to the volatile but potentially lucrative medical technology sector.